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Abstract
Background and aim: Comorbidities are known to exist in many rheumatological conditions. Polymyalgia
rheumatica (PMR) is a common inflammatory rheumatological condition affecting older people which, prior to
effective treatment, causes severe disability. Our understanding of associated comorbidities in PMR is based only
on case reports or series and small cohort studies. The objective of this study is to review systematically the
existing literature on the comorbidities associated with PMR.
Methods: MEDLINE, EMBASE, PsycINFO and CINAHL databases were searched for original observational research
from inception to November 2016. Papers containing the words ‘Polymyalgia Rheumatica’ OR ‘Giant Cell Arteritis’
OR the terms ‘PMR’ OR ‘GCA’ were included. Article titles were reviewed based on pre-defined criteria by two
reviewers. Following selection for inclusion, studies were quality assessed using the Newcastle–Ottawa tool and
data were extracted.
Results: A total of 17,329 papers were reviewed and 41 were incorporated in this review, including three published
after the search took place. Wide variations were found in study design, comorbidities reported and populations
studied. Positive associations were found between PMR diagnosis and stroke, cardiovascular disease, peripheral
arterial disease, diverticular disease and hypothyroidism. Two studies reported a positive association between
PMR and overall malignancy rate. Seven studies reported an association between PMR and specific types of
cancer, such as leukaemia, lymphoma, myeloproliferative disease and specified solid tumours, although nine
studies found either no or negative association between cancer and PMR.
Conclusion: Quantification of the prevalence of comorbidities in PMR is important to accurately plan service
provision and enable identification of cases of PMR which may be more difficult to treat. This review highlights
that research into comorbidities in PMR is, overall, methodologically inadequate and does not comprehensively
cover all comorbidities. Future studies should consider a range of comorbidities in patients with a validated
diagnosis of PMR in representative populations.
Keywords: Polymyalgia rheumatica, Giant cell arteritis, Systematic review, Comorbidities, Multimorbidity,
Epidemiology
Introduction
Polymyalgia rheumatica (PMR) is the most common in-
flammatory rheumatological condition affecting people
over the age of 50 years [1]. Symptoms include muscle
stiffness and pain, predominantly around the neck or
shoulder and pelvic girdles [2], as well as a low-grade
fever, depression, fatigue, anorexia and weight loss [3, 4].
Raised inflammatory markers (erythrocyte sedimentation
rate (ESR) or C-reactive protein (CRP)) are a hallmark of
this condition. PMR is usually treated with medium/low
dose oral glucocorticoids (GCs) which are gradually re-
duced and stopped over several years [5].
Patients with common inflammatory rheumatological
conditions, for example gout [6] and rheumatoid arthritis
(RA) [7], are predisposed to developing cardiovascular dis-
ease (CVD). In patients with RA, this risk has been attrib-
uted to an increased prevalence of arterial atherosclerotic
plaques [8, 9], the quantity of which are correlated with
levels of systemic inflammation [10] and duration of
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rheumatological disease [11]. Patients with RA are also
known to have a higher risk of lung diseases [12] and cer-
tain types of cancers, particularly haematological cancers
[13]. PMR, like RA, is a rheumatological condition charac-
terised by increased levels of inflammation, and therefore
patients with PMR may have a similar predisposition to
increased risks of certain conditions.
In order to diagnose PMR, guidelines endorsed by the
American College of Rheumatology and the European League
Against Rheumatism advise the exclusion of conditions which
may cause similar symptoms [14]. These include core exclu-
sion conditions (GCA, cancer and infections) as well as RA,
fibromyalgia, hypothyroidism and drug-induced myalgia. The
guidelines also suggest an evaluation of whether patients have
comorbidities that put them at greater risk of side effects
from GC treatment [14]. Quantifying the burden of comor-
bidities in this group of patients is therefore important.
The age group (typically over 50 years) most commonly af-
fected by PMR frequently has more than one comorbidity.
Aging is an important predictor of multimorbidity; a recent
Scottish study found the number of adults with two or more
chronic conditions increased from 30.4% between age 45
and 64 years, to 64.9% in those aged 65–84 years, to greater
than 80% in those aged over 85 years [15]. This systematic
review aims to summarise the available evidence of the co-
morbidity profile of people with PMR, and will be the first
review to assess comprehensively the evidence for all comor-
bidities and whether there is evidence for multiple comor-
bidities existing together. If the evidence shows that patients
with PMR commonly have multiple comorbidities then these
may no longer be viewed as exclusion criteria precluding a
diagnosis of PMR, potentially revealing the true burden of
PMR to be higher than currently recognised.
Methods
We conducted a systematic review and narrative synthesis
of research literature. We searched medical bibliographic
databases to identify articles containing data on any comor-
bidity either preceding or following a diagnosis of PMR.
Data sources, searches and study selection
The search was conducted in MEDLINE, EMBASE, Psy-
ciINFO and CINAHL from their inception until the date
of search in November 2016. Additional articles were
found by examining reference lists of included studies
and an updated search was run in June 2018 which led
to the inclusion of a further study. The exploded MeSH
terms ‘polymyalgia rheumatica’ and ‘giant cell arteritis’
were used in combination with text word searches for
the same as well as for ‘PMR’ and ‘Giant Cell Arteritis’
(GCA). GCA is a vasculitis which very commonly
co-occurs with PMR; around 10–30% of patients with
PMR develop GCA during the course of their illness [16,
17]. Given this overlap in conditions, GCA was included
to increase the likelihood of ensuring that all studies in
which PMR comorbidities were considered were in-
cluded in the review. PRISMA guidelines were followed
throughout the review process [18].
All article titles identified were screened by a single re-
viewer (RP) against the inclusion and exclusion criteria.
A random sample of 100 of these titles was reviewed by
a second reviewer (TH) and agreement between deci-
sions was assessed using adjusted κ calculation [19]. All
selected abstracts were then assessed by two reviewers
(RP and TH). Any citation thought to be eligible by ei-
ther reviewer was carried forward to full text review.
Reasons for exclusion were recorded. Finally, the
remaining full texts were reviewed by the same two au-
thors and a list of papers to be included in the narrative
synthesis was created.
Inclusion and exclusion criteria
The inclusion criteria for this review included: a sample of
patients with PMR and at least one comorbidity; and the
study design must be either cross-sectional, case–control or
a prospective or retrospective cohort study. Exclusion cri-
teria were: patients under the age of 40 years; randomised
control trials (RCTs); and review articles or conference ab-
stracts. PMR is a disease of older adults. In order to make a
diagnosis of PMR, clinical guidelines suggest patients must
be aged over 50 years [20], therefore patients under 40 years
old are likely to represent misdiagnosis. RCTs were ex-
cluded as we wished to look at representative samples of
patients with PMR drawn from real-world, observational
data. Review articles and conference abstracts were not in-
cluded to ensure all articles were peer reviewed and fully
referenced. In order to ensure that all conditions repre-
sented true comorbidities, rather than secondary complica-
tions of GC treatment in PMR, we excluded trials which
reported only complications of GC therapy [3, 21–27].
There were no date or language restrictions although all
included studies were in English. Potentially relevant stud-
ies that contained data on GCA were included until full
text review due to the overlap between PMR and GCA. If,
at that point, the paper only contained data about GCA, it
was excluded. The reference lists of other systematic re-
views that had assessed individual comorbidities related to
PMR were also reviewed to reduce the chance of missing
relevant studies.
Quality assessment
Both reviewers, using the Newcastle–Ottawa Scale for
case–control and/or cohort studies [28], evaluated the
quality of studies. This scale was chosen as it is endorsed
for use in systematic reviews of non-randomised trials
by the Cochrane Collaboration [29].
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Data extraction
A standardised form was developed and used by both re-
viewers independently to ensure the accuracy of data extrac-
tion (Additional file 1). The primary outcome of interest
was the total number of patients with PMR who developed
a comorbidity of interest compared to controls (without
PMR). Other data extracted included clinical criteria used to
diagnose PMR, study design, comorbidity under investiga-
tion and its temporal relationship to PMR. Meta-data from
each study, such as lead author name, publication year, sex,
age, country and healthcare setting, were also extracted. Co-
morbidities were categorised into four groups: malignant
disease, particularly haematological malignancies; vascular
disease, including coronary, cerebroarterial and peripheral
arterial disease; mortality; and other comorbidities (e.g.
endocrine, psychiatric and neurological diseases).
Data analysis
Using the total number of patients with PMR and, if
present, their controls we attempted to aggregate data to
obtain pooled estimates of prevalence of comorbidities
and odds ratios to quantify the strength of any apparent
association.
Results
Search results
A total of 27,698 articles were identified in this search
with a further seven identified following review of refer-
ences of other articles. Of this total, 10,376 were re-
moved due to duplications, leaving 17,329 unique
articles. Following application of inclusion and exclusion
criteria during screening of titles, 17,042 further cita-
tions were excluded. Of the random selection of 100 of
these articles which were reviewed by a second author,
agreement between authors was excellent (κ = 0.86).
The abstracts of 287 studies were assessed for eligibil-
ity, and 131 were excluded at this stage. The full texts of
articles were reviewed and 41 were retained for data ex-
traction [30–70]. This process, which followed PRISMA
guidelines, including reasons for exclusion of studies
[18], is illustrated in Fig. 1.
Articles included in the review
Of the 41 included studies, 32 were cohort studies [30–61]
and nine were case–control studies [62–70]. Eighteen of
the cohort studies did not use a formal comparator group.
Of the 14 cohort studies with controls, six were based on
national datasets, whereas eight were based either on local
datasets or on patients presenting to clinics at the same
hospital. PMR cases were defined from medical records in
16 studies, national registries in 19 studies and national da-
tabases in the remaining six studies. Co-existent GCA cases
were formally excluded in six studies and included, or not
explicitly excluded, in 35 studies. All but one study was
from Europe (predominantly Scandinavia) or the United
States. Included studies are tabulated in Additional file 2.
PMR and cancer
Seven studies, reporting 12 outcome measures, have
assessed the risk of cancer diagnosis prior to PMR onset
(Table 1). All of these studies excluded PMR diagnoses
made in the year prior to diagnosis of cancer, to reduce
the risk of reverse causality (i.e. cancer causing PMR or
PMR symptoms). Of these, the rate of haematogenous
cancers was significantly higher among patients with
PMR in five cases, while the other seven were
non-significantly different.
Six studies reported prospective rates of any cancer
diagnosis after diagnosis with PMR (Table 2); two
showed an increase in the proportion of people with
PMR who developed cancer compared to controls, two
were equivocal and the remaining two found the
opposite.
In six prospective cohort studies the risk of 17 types of
cancer following diagnosis with PMR was considered.
Two studies showed an increase in the risk of Hodgkin’s
lymphoma [55] and non-Hodgkin’s lymphoma [56]. Of
the remaining four studies, three reported no difference
in the rates of female cancers [51], upper gastrointestinal
cancers [47] or myeloma [54]. The final study reported
no difference in mortality following diagnosis with
gastrointestinal cancers [50] among people with or with-
out PMR.
PMR and vascular disease
A number of studies (n = 8) have assessed a variety of
different vascular diseases in patients with PMR
(Table 3). Fifteen outcome measures were reported, al-
though only seven gave comparable figures for patients
without PMR. In each study with a comparator group
the proportion of people with PMR who developed vas-
cular disease was higher compared to controls.
PMR and mortality
Few studies have assessed the association between PMR
and mortality (n = 4). Three studies reported reduced
mortality among patients diagnosed with PMR [35, 38, 39]
while one study found an increase, but this study did not
differentiate between patients with PMR and GCA [36].
PMR and other comorbidities
An association between thyroid disease and PMR is un-
proven. Bowness et al. [31] found an increase in the risk
of hypothyroid disease (RR 3.2 (95% confidence interval
1.71, 5.91)), but Juchet et al. [33] did not. One recent
case–control study found a significantly increased rate
of diverticular disease prior to a diagnosis with PMR
(OR 4.06 (95% CI 1.76–9.35)) [70].
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No evidence has been found to associate PMR with psy-
chiatric comorbidities, including schizophrenia [44, 69]
and bipolar disease [44]. Li et al. [49] found a potential as-
sociation between PMR and Parkinson’s disease (SIR 1.25
(95% CI 1.01, 1.53)). Hemminki et al. [53] also reported an
association between PMR and hospitalisation due to obes-
ity (SIR 1.65 (95% CI 1.22, 2.19)).
A small number of studies from the United States (n =
2) [40, 59] looked at wide ranges of different comorbidities
but their sample size was insufficient to find significant as-
sociations for the majority of the comorbidities.
Quality assessment
All of the articles in this study used medical records or
nationwide registries (based on medical records) to cor-
roborate diagnosis of PMR and the comorbidity; there-
fore, they were awarded three or four stars for cohort or
case selection using the Newcastle–Ottawa criteria. All
studies also achieved at least two stars for outcome
measurement. However, many of the studies failed to re-
cruit a comparator group, instead using the population
as a reference, and therefore comparability scores were
low (Additional file 2).
Many of the cohort studies identified failed to include
comparison groups (n = 18), instead using indirect
standardisation to calculate incidence or mortality ratios.
The lack of comparison groups limits the generalisability
of many of the studies. Further to this, almost half of the
studies (n = 19) sourced their sample of patients with
PMR based on hospital discharge data. This may be an
appropriate approach for some autoimmune conditions,
but the majority of patients with PMR are managed in
primary care settings [71, 72].
Aggregation of data to calculate pooled odds and haz-
ard ratios was attempted for vascular disease and cancer
diagnoses; however, high levels of heterogeneity were
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Fig. 1 Flowchart of study inclusion, adopted from Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18].
GCA giant cell arteritis
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found between the studies (88–100%) and therefore this
was not reported.
Many of the studies limited themselves to a small
number of comorbid conditions, thus not allowing a pic-
ture of the overall health of patients with PMR to de-
velop. Two studies [34, 40] did attempt to look at a
range of comorbidities but they were underpowered.
Discussion
Statement of principle findings
This review found some evidence of an association be-
tween PMR and vascular disease, and possibly cancer,
particularly in the first 6 months following diagnosis.
However, the evidence for this is not robust.
The concentration of the apparent association between
PMR and cancer in the first 6 months following diagno-
sis suggests the possibility of an element of misdiagnosis.
This could occur as some of the features of PMR (myal-
gia, fatigue, weight loss, raised inflammatory markers)
are also non-specific early features of some cancers. Fur-
thermore, as time passed, the rate of diagnosis of cancer
was found to drop down to the background population
rate.
Regarding specific types of cancer, some studies have
proposed there could be associations between PMR and
haematological cancers. This includes Hodgkin’s and
non-Hodgkin’s lymphoma [56], myeloma [68] and other
myeloid malignancies [63, 66]. An increase in the risk of
lymphoma has been observed with RA, which has been
postulated to be due to higher accumulated inflamma-
tory activity in RA [73]; a similar mechanism may lie be-
hind the apparent increase in patients with PMR.
The overall trend of results suggests that PMR may be as-
sociated with an increased risk of the development of vas-
cular disease. Knowing that both PMR and RA are
inflammatory conditions, there is biological plausibility that
PMR and vascular disease could be associated. However,
the two largest studies, both based on population data from
the UK, reported conflicting results: Hancock et al. [58]
stated that PMR was significantly associated with vascular
disease, while Pujades-Rodriguez et al. [60] reported a re-
duction in the risk (incidence rate ratio 0.88 (95%
CI 0.83–, 0.94)). However, in the latter study when only pa-
tients with PMR were included, there was a slight increase
in the proportion of patients with the condition who went
Table 2 Cancer following diagnosis with PMR
Prospective cohort with combined cancer cases
PMR patients Control patients
Study PMR
cases
(n)
Cancer
cases
(n)
Proportion
(%)
Controls
(n)
Cancer
cases
(n)
Proportion
(%)
Muller et
al. [57]
2877 667 23.18 9942 1938 19.49
Bellan et al.
[61]
100 24 24.00 702 41 5.84
Ji et al. [45] 35,918 3941 10.97 – – –
Myklebust
et al. [37]
366 34 9.29 1324 143 10.80
Haga et al.
[32]
91 10 10.99 794 131 16.50
Pfeifer et
al. [59]
359 66 18.38 357 62 17.37
Totala 39,711 4742 21.12 13,119 2315 17.65
PMR polymyalgia rheumatica
aJi et al. [45] not included in calculation as no control group
Table 1 Cancer prior to diagnosis with PMR
Retrospective case–control study
Study Diagnosis Cases (n) PMR
cases (n)
Controls (n) PMR
controls (n)
Odds ratio
(95% CI)
Case
rate (%)
Control
rate (%)
Anderson et al. [64] Lymphoid malignancies 33,721 344 122,531 1244 0.9 (0.8–1.0) 1.02 1.02
Anderson et al. [63] Myeloid malignancy 9998 125 160,086 1288 1.7 (1.4–2.1) 1.25 0.80
Myelodysplastic malignancy 3758 55 42,886 518 1.5 (1.1–2) 1.46 1.21
Anderson et al. [67] HCL 418 9 160,086 2721 1.5 (0.5–3.9) 2.15 1.70
Askling et al. [62] All lymphoma 42,676 114 78,487 250 0.8 (0.7–1.0) 0.27 0.32
NHL 28,355 88 52,164 187 0.9 (0.7–1.1) 0.31 0.36
HL 4037 3 7394 15 0.4 (0.1–1.3) 0.07 0.2
CLL 10,555 24 19,391 52 0.8 (0.5–1.4) 0.23 0.27
Kristinsson et al. [66] Any MPN 11,039 46 43,550 104 1.7 (1.2–2.5) 0.42 0.24
Lanoy and Engels [65] Cutaneous NHL 2652 19 178,452 1731 0.7 (0.5–1.1) 0.72 0.97
Lindqvist et al. [68] MM 19,112 56 75,408 116 1.9 (1.4–2.6) 0.29 0.15
MGUS 5403 58 21,209 79 2.9 (2.1–4.1) 1.07 0.37
PMR polymyalgia rheumatica, HCL hairy cell leukaemia, NHL non-Hodgkin’s lymphoma, HL Hodgkin’s lymphoma, CLL chronic lymphocytic leukaemia, MM multiple
myeloma, MPN myeloproliferative neoplasm, MGUS monoclonal gammopathy of undetermined significance
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on to have a vascular event compared to controls (23.24%
compared to 20.43%).
These two studies employed similar approaches select-
ing with PMR from linked UK databases. However, a
number of differences existed between the studies, in-
cluding the age of participants (> 50 years only for Han-
cock et al. [58] and > 18 years for Pujades-Rodriguez et
al. [60]), average years of follow up (7.8 and 3.13 years
respectively) as well as the total number of patients
found with PMR (3249 compared to 11,320 patients).
Potentially, the variation in risk of vascular events be-
tween these studies could be explained by the differences
in follow up or the age distribution of the study
population.
Another reason for inconsistent evidence of an in-
crease in vascular risk for patients with PMR may be the
modulating effect that GCs have upon levels on inflam-
mation. If the risk of vascular disease correlates with the
presence of inflammation in the body, GC therapy would
reduce this, which may then also reduce vascular risk.
The study by Kremers et al. [42] appears to bear this
out. In this study, the risk of vascular events was lower
in patients with PMR who were treated with GCs com-
pared to those who were not. Further to this, Hancock
et al. [58] reported that the excess vascular risk in PMR
reduced over time; this could reflect declining levels of
inflammation.
Overall, although some studies dissent from this view,
it appears that a diagnosis of PMR increases an individ-
ual’s risk of vascular disease. However, further research
in this area is needed to add clarity.
Conversely, it appears that a diagnosis with PMR is as-
sociated with a reduction in mortality. This was demon-
strated in three out of the four studies that reported it as
an independent outcome. A possible explanation for this
could again be surveillance bias. Patients with chronic
illness (and especially PMR where regular assessment,
follow up and monitoring are advised) are more likely to
be under active follow up for their condition and any de-
veloping morbidity, particularly if related to well-recog-
nised adverse effects of treatment, is likely to be
identified and managed earlier.
There is a small amount of evidence that patients with
PMR may be more likely to develop hypothyroidism [31]
and Parkinson’s disease [49]. PMR and hypothyroidism
both preferentially affect females, and therefore a similar
autoimmune pathway may be present in both conditions.
However, as has been pointed out, PMR does not share
all of the characteristics of traditional autoimmune con-
ditions, for example it lacks specific autoantibodies [74].
Table 3 Vascular disease and PMR
PMR patients Control patients
Study PMR cases
(n)
Comorbid
condition (n)
Proportion
(%)
Controls
(n)
Comorbid
condition (n)
Proportion
(%)
Stroke
Kang et al. [46] 781 113 14.47 3905 273 6.99
Zoller et al. [48] 16,496 1981 12.01
Kremers et al. [42] 276 58 21.01
Hancock et al. [58] 3249 397 12.22 12,735 556 4.37
Myocardial infarction
Kremers et al. [42] 276 47 17.03
Hancock et al. [58] 3249 460 14.16 12,735 575 4.52
Zoller et al. [48] 21,351 5669 26.55
Heart failure
Kremers et al. [42] 276 68 24.64
Peripheral vascular disease
Kremers et al. [42] 276 35 12.68
Hancock et al. [58] 3249 140 4.31 12,735 151 1.19
Warrington et al. [43] 353 38 10.76 705 28 3.97
Combined
Kremers et al. [42] 276 208 75.36
Hancock et al. [58] 3249 918 28.25 12,735 1150 9.03
Pujades-Rodriguez et al. [60] 9776 2272 23.24 105,504 21,559 20.43
Bengtsson and Malmvall [30] 73 16 21.92
PMR polymyalgia rheumatica
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Furthermore, it seems that PMR is not associated as
strongly with other autoimmune conditions as would be
expected if it was a pure autoimmune disease. Parkin-
son’s disease is a condition which predominantly affects
older people, as does PMR, and therefore this associ-
ation may just be a result of clustering of diagnoses in
an older population.
Strengths and weaknesses
The main strength of the study was its deliberately broad
scope and aim to include any study in which the risk of
any comorbidity either before or after diagnosis with
PMR was to be reviewed. Following the initial broad
search, articles from the ‘grey literature’ were excluded
and only articles fully published in peer-reviewed jour-
nals were included.
The potential limitations in this study arose not due to
the protocol but rather because the majority of studies
were of relatively poor quality. These risks included se-
lection bias, surveillance bias and a lack of adequate
control groups.
Selection bias within the included studies is a possibil-
ity in this review, as the majority of studies drew PMR
cases from secondary care, either from hospital dis-
charge data or from rheumatology outpatient clinics.
Current UK guidelines suggest only referring atypical
cases, cases of diagnostic uncertainty or treatment pre-
dicaments [5, 14], meaning that in the UK 71–84% of
patients with PMR are treated in the community by pri-
mary care physicians [71, 72]. Therefore, the patient
population in these studies may not accurately reflect
the majority of those who are diagnosed with PMR. This
may have artificially inflated the apparent differences in
development of comorbidities between patients with and
without PMR.
Another limitation is the risk of surveillance bias as
discussed earlier around the apparent reduction in mor-
tality [75]. Some case–control studies attempted to deal
with this by excluding comorbid disease found in the
year prior to diagnosis [63, 64, 67, 68], while in two ob-
servational cohort studies [58, 60], controls were se-
lected that had contacted a primary care service in the
year the index cases were diagnosed. Finally, many of
these studies assessed multiple variables, often > 30 dif-
ferent autoimmune conditions, increasing the likelihood
of a chance finding (type II error).
Furthermore, we also noted that the range of comor-
bidities reported in the literature was more limited than
we expected; for example, there were no studies which
explicitly examined the risks of important and common
conditions such as diabetes mellitus and asthma or other
chronic respiratory conditions.
A further potential bias is the effect of GC therapy and
the impact of this on the risks of comorbidities. As GC
is the only widely accepted treatment for PMR, we could
not exclude studies where patients were treated with
GC. To reduce the impact of potential bias from GC
treatment, we excluded studies in which direct compli-
cations of GC therapy were assessed. However, as dis-
cussed previously in relation to vascular risk, GC
therapy is inevitable in PMR and therefore we could not
completely mitigate this effect.
Conclusion
This review has found the overall standard of evidence
regarding the association of comorbidities with PMR to
be weak. There may be an increased risk of vascular dis-
ease and possibly cancer in patients with PMR. Weaker
quality evidence also suggests that patients with PMR
have a reduced mortality rate. Currently, there is little
evidence around the wider health of patients with PMR
either at the time of diagnosis or in the period following.
This lack of firm evidence around which comorbidities
exist alongside or are potentially associated with PMR
presents a problem for the pragmatic clinician. Current
clinical guidelines suggest that in order to diagnose
PMR, a large number of other conditions which may
mimic the symptoms of PMR should be excluded. This
list includes, but is not limited to, rheumatoid arthritis
and endocrine, infective and neoplastic conditions [14].
However, comorbidities are very common in the age
group affected by PMR [76], and therefore the coexist-
ence of one of these comorbidities with PMR should not
necessarily prevent or invalidate the diagnosis of PMR.
The uncertainty around the general health of patients
with PMR and comorbidities that may coexist with it
presents a challenge for healthcare practitioners who
deal most with this condition, be they from primary or
secondary care. A rigorous diagnostic and follow-up
process is crucial to ensure this uncertainty does not
translate into misdiagnosis. In the future, it is important
to confirm whether, and if so to what extent, a diagnosis
of PMR imparts an excess risk of vascular disease or
cancer.
Further research in the form of large observational
studies, based in primary care, of the health of patients
with PMR, including the prevalence of comorbidities be-
fore and after diagnosis, would allow clinicians to better
monitor for these outcomes.
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